{"id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased levels of mRNA"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased levels of mRNA"},{"drug":"CYP3A4 inducers","action":"Monitor","effect":"Decreased levels of mRNA"},{"drug":"CYP3A4 inhibitors","action":"Monitor","effect":"Increased levels of mRNA"}],"commonSideEffects":[{"effect":"Injection site pain (PAIN)","drugRate":"82.7%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":86,"trialsReporting":1},{"effect":"Fatigue (FATIGUE)","drugRate":"73.1%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":76,"trialsReporting":1},{"effect":"Headache (HEADACHE)","drugRate":"52.9%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":104,"totalAffected":55,"trialsReporting":1},{"effect":"Myalgia (MUSCLE PAIN)","drugRate":"35.6%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":104,"totalAffected":37,"trialsReporting":1},{"effect":"Chills (CHILLS)","drugRate":"21.2%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":22,"trialsReporting":1},{"effect":"Arthralgia (JOINT PAIN)","drugRate":"18.3%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":104,"totalAffected":19,"trialsReporting":1},{"effect":"Diarrhoea (DIARRHEA)","drugRate":"14.4%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":104,"totalAffected":15,"trialsReporting":1},{"effect":"Injection site swelling (SWELLING)","drugRate":"10.6%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":11,"trialsReporting":1},{"effect":"Injection site erythema (REDNESS)","drugRate":"5.8%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":6,"trialsReporting":1},{"effect":"COVID-19","drugRate":"2.9%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":3,"trialsReporting":1},{"effect":"Pyrexia (FEVER)","drugRate":"1.9%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":2,"trialsReporting":1},{"effect":"Vomiting (VOMITING)","drugRate":"1.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":104,"totalAffected":1,"trialsReporting":1},{"effect":"Back pain","drugRate":"0.0%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Bell's palsy","drugRate":"0.0%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Blood pressure increased","drugRate":"0.0%","organSystem":"Investigations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Ear pain","drugRate":"0.0%","organSystem":"Ear and labyrinth disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Fatigue","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Headache","drugRate":"0.0%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Hypercholesterolaemia","drugRate":"0.0%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Injection site pain","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Joint abscess","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Lymphadenopathy","drugRate":"0.0%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Myalgia","drugRate":"0.0%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Otitis media","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Sinusitis","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Thermal burn","drugRate":"0.0%","organSystem":"Injury, poisoning and procedural complications","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Upper respiratory tract infection","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Urinary tract infection","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Vomiting","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Vulvovaginal mycotic infection","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Vulvovaginal pruritus","drugRate":"0.0%","organSystem":"Reproductive system and breast disorders","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1}],"contraindications":["Do not administer COMIRNATY to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of COMIRNATY [see Description (11)] or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of a Pfizer-BioNTech COVID-19 vaccine."],"specialPopulations":{"Pregnancy":"No specific guidance is mentioned for pregnancy in the given text.","Geriatric use":"The bivalent COVID-19 vaccine is recommended for adults aged ≥65 years.","Paediatric use":"The bivalent COVID-19 vaccine is recommended for children aged 6 months–5 years and ≥6 years.","Renal impairment":"No specific guidance is mentioned for renal impairment in the given text.","Hepatic impairment":"No specific guidance is mentioned for hepatic impairment in the given text."},"seriousAdverseEvents":[{"event":"Acute kidney injury","detail":"Renal and urinary disorders. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Gastroenteritis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Normocytic anaemia","detail":"Blood and lymphatic system disorders. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Adenocarcinoma pancreas","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Alcohol poisoning","detail":"Injury, poisoning and procedural complications. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Arrhythmia","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Back pain","detail":"Musculoskeletal and connective tissue disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Biliary colic","detail":"Hepatobiliary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Diverticulitis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Enterocolitis infectious","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Hypoglycaemia","detail":"Metabolism and nutrition disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Hypokalaemia","detail":"Metabolism and nutrition disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Hypotension","detail":"Vascular disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Left ventricular failure","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Leukaemia","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Pancreatitis acute","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Post procedural infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Prostate cancer","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Small intestinal obstruction","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Suicidal ideation","detail":"Psychiatric disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Syncope","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Testicular germ cell cancer","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Type 2 diabetes mellitus","detail":"Metabolism and nutrition disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Urinary tract obstruction","detail":"Renal and urinary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"}]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=bnt162b6-bivalent-original-omi-ba-4-ba-5","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:40:31.209787+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:40:38.446190+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:40:31.230284+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bnt162b6-bivalent-original-omi-ba-4-ba-5","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:40:39.088443+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5791340/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:40:39.972588+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T08:28:19.828366+00:00"}},"allNames":"bnt162b6 bivalent (original/omi ba.4/ba.5)","offLabel":[],"timeline":[],"aiSummary":"Pfizer's BNT162b6 Bivalent is a marketed COVID-19 vaccine for individuals 12 years and older, with certain immunocompromised individuals also eligible. It is a bivalent vaccine, targeting both the original and OMI BA.4/BA.5 strains. The vaccine has generated significant revenue, with $63.6B in sales. Its key indications include COVID-19 prevention in various age groups and immunocompromised individuals. The vaccine's mechanism is not explicitly stated, but it is a mRNA-based vaccine. Pfizer's BNT162b6 Bivalent has become a significant player in the COVID-19 vaccine market. The company continues to develop and refine its vaccine pipeline.","brandName":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","ecosystem":[],"isGeneric":true,"mechanism":{"target":"SARS-CoV-2 spike protein","novelty":"best-in-class","modality":"mRNA-based","drugClass":"vaccine","explanation":"","oneSentence":"","technicalDetail":"BNT162b6 Bivalent is a bivalent vaccine, meaning it targets two different strains of the COVID-19 virus: the original strain and the OMI BA.4/BA.5 strain. The vaccine uses a modified version of the SARS-CoV-2 spike protein to stimulate an immune response. The vaccine has been shown to be safe and effective in clinical trials, with a strong immune response and minimal side effects."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=bnt162b6-bivalent-original-omi-ba-4-ba-5","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bnt162b6-bivalent-original-omi-ba-4-ba-5","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T08:28:21.138398+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Comirnaty","company":"Pfizer","advantage":"elicited T cell responses were quantified by ELISpot both ancestral Wuhan-Hu-1 spike and Omicron BA.4/BA.5 spike, than the monovalent V3"},{"name":"BNT162b","company":"Pfizer","advantage":"elicited potent and broad nAbs, and exhibited high efficacy in protecting these animals from Omicron subvariants’ challenges"},{"name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5) (bnt162b6-bivalent-original-omi-ba-4-ba-5)","company":"Pfizer","advantage":"elicited broad immune responses and protection against Omicron subvariants infection"},{"name":"BNT162b (Omicron BA.1-Adapted)","company":"Pfizer","advantage":"elicited potent and broad nAbs, and exhibited high efficacy in protecting these animals from Omicron subvariants’ challenges"}],"genericName":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indications":{"approved":[{"name":"COVID-19 prevention in individuals 12 years of age and older","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 5 years of age and older","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 6 months through 4 years of age","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 5 years of age and older with certain immunocompromised individuals","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 12 years of age and older with certain immunocompromised individuals","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 6 months through 4 years of age with certain immunocompromised individuals","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 5 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 12 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 6 months through 4 years of age with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05472038","phase":"PHASE2, PHASE3","title":"A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-07-26","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":1453}],"_emaApprovals":[{"date":"","name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL5791340","moleculeType":null,"molecularWeight":"319.43"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL5791340"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[{"hr":"2.91","nctId":"NCT05472038","phase":"PHASE2, PHASE3","pValue":"","ciLower":"2.45","ciUpper":"3.44","endpoint":"GMR of Omicron (BA.4/BA.5)- NT of BNT162b2 Bivalent [WT/ OMI BA.4/ BA.5] 30 mcg Cohort 2 (Group 4)/ Cohort 3 (Group 2) Combined in C4591044 Compared to NT of BNT162b2 30 mcg in C4591031 [NCT04955626]- 1 Month After Vaccination Among Participants >55 Years","enrollment":1453}],"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"mRNA-based","firstApprovalDate":"","enrichmentLevel":5,"visitCount":9,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T08:28:21.138398+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}